Zydus Cadila has received the final approval from the USFDA to market Succinylcholine Chloride Injection USP, 200 mg.’10 mL (20 mg/mL) multiple-dose vials. It is used as an adjunct to generalanesthesia,to facilitate tracheal intubation,and to provide skeletal muscle relaxation during surgery or mechanical ventilation. It will be manufactured at the group’s formulations manufacturing facility at Moraiya, Ahmedabad.
The group also received the tentative approval for Plerixafor Injection, 24 mg/l.2 mL (20 mg/mL), single-dosevial. It is usedto mobilize hematopoieticstemcells into the bloodstream for their collection & subsequent transplantation in patients with certain type of blood cancers. It will be manufactured at Alidac Pharmaceuticals Ltd., a wholly owned subsidiary of Cadila Healthcare Ltd., located at the pharma SEZ in Ahmedabad.
The group now hasmore than 190approvalsandhassofar filed over 320 ANDAs since the commencement of the filing process in FY 2003-04.
Shares of CADILA HEALTHCARE LTD. was last trading in BSE at Rs.389.65 as compared to the previous close of Rs. 393.65. The total number of shares traded during the day was 51921 in over 1489 trades.
